www.ias2011.org
Epidemiology of HIV Transmissed Drug Resistance Mutations.
Amilcar Tanuri, MD, PhD.Head of Laboratório de Virologia Molecular, UFRJ, Brazil.
Senior Lab Advisor ICAP, Columbia University, NY, USA.
Sic Transit Gloria Mundi. Ad Majorem Dei Gloriam In
Hoc Signo Vinces.
www.ias2011.org
ARV Resistance in Treated Individuals
• HIV DR Decreasing since initiation of triple therapy
• DR is low in those using RTV boosted PI's• DR can be managed by new drugs within
existing classes and new classes
www.ias2011.org
Transmission of Drug Resistance in HIV
• ARV treated individuals living longer• Incident infections continue to increase
worldwide• Transmitted resistance well recognised in
countries with wide ARV coverage
www.ias2011.org
Transmission of Resistance in Europe
www.ias2011.org
Overall prevalence of TDR in German Seroconverter Cohort 1997–2007.
Barbara Bartmeyer et al. PLoS ONE, 2010 , (5)10: e12718.
www.ias2011.org
Trend of TDR in San Francisco , USA
Vivek Jain et al. PLoS ONE, December 2010 (5) Issue 12, e15510.
www.ias2011.org
Trend of TDR in San Francisco , USA
Vivek Jain et al. PLoS ONE, December 2010 (5) Issue 12, e15510.
www.ias2011.org
Prevalence of Mutations with Reduced Antiretroviral-Drug
Susceptibility
Weinstock et al. JID 2004;189:2174-80.
1082 HIV-infected Persons in the U.S.
02468
10121416
Men who have sex with men
Heterosexual men
Women
African
Hispanic
White
%
www.ias2011.org
In resource rich world, transmitted resistance appears to be stabilising or even
reducing (UK data)
UK Collaborative Group on HIV Drug Resistance.AIDS 2007;21:1035-9.
Chronic infection
Acute infection
14
12
10
8
6
4
2
0
1997 1998 1999 2000 2001 2002 2003 2004 2005
Year of sample
Sam
ple
s w
ith
IA
S m
uta
tio
n(s
) (%
)
www.ias2011.org
Trend of TDRM rate found in different surveys done in Rio de Janeiro .
0
2
4
6
8
10
12
1996 1998 2000 2002 2003/4 2007/8 2009/10
DRM rate
www.ias2011.org
Trend of TDRM Pattern in Rio de Janeiro, Brazil.
0
1
2
3
4
5
6
7
1996
1998
2000
2002
2003/4
2007/8
2009/10
www.ias2011.org
www.ias2011.org
HIV Carrying DRM can be tramissed and can give rise to micro-epidemics
Brenner et al. 2008; AIDS, 22(18): 2509–2515
www.ias2011.org
17
119
5
Rep
licati
on
Cap
acit
y
Wrin T, 40th ICAAC 2000
Impact in RC of DRM
www.ias2011.org
Retention of DRM without ARV selection in B na C isolates in vitro.
5 10 15 20 25 30 35 40 45 50 55 60 650
10
20
30
40
50
60
70
80
90
100
WASH OUT PR B Vs. C
M46I-B
M46I-C
54V-B
54V-C
82A-B
82A-C
90M-B
90M-C
CULTURE DAYS
% R
ES
IST
AN
CE
MU
TA
TIO
N
Gonzalez LM. et al. J Gen Virol. 2006 (5):1303-9.
www.ias2011.org
Persistence of Transmitted Resistance in Primary HIV Infection
n=9Persistent resistance
n=2Reversion to wild type
n=14Persistent resistance
n=2Reversion to wild type
Variable persistence according to mutations: TAMs persist, K103N persists, some PI persist (M46I, L90M), MDR can persist
n=11Primary resistance
US; F/U median 9 months
n=16Primary resistance
UK; F/U up to 3 years
Little et al. 11th CROI 2004, San Francisco, CA. Abs 36LB.Pao et al. JAIDS 2004;37:1570-3.
www.ias2011.org
DART TRIAL ZDV/3TC/TDF
MutationWeek 24(n=24)
Week 48(n=41*)
M184V 15 (62%)
32 (78%)
K65R 3 (12%)
6 (15%)
M41L 7 (29%)
17 41%)
D67NG 9 (38%)
23 (56%)
K70R 8 (33%)
23 (56%)
L210W 0 (0%)
3 (7%)
T215FY 7 (29%)
17 (41%)
K219QEN 1 (4%)
9 (22%)
Total TAMs: 01–34–6
10 (42%)
13 (54%)
1 (4%)
11 (27%)18 (44%)12 (39%)
TAM Group** I II
I and II
5 (36%)
4 (11%)
5 (36%)
2 (7%)11 (37%)17 (57%)
Pillay et al. CROI 2007. Abstr. 642.
Prevalence of mutations at 24 and 48 weeks in absence of virological monitoring
www.ias2011.org
Baseline Resistance in DART Trial
• 8/91 with resistance (9%)• 41L, • 108I, • 103N+190A, • 41L+70R+184V• 41L, • 103N+184V, • 103N+181C+184V, • 67N+181C+184V
Drugs Compromised
Nucleoside analogues: 41L, 70R, 67N
3TC: 184V
NNRTI: 103N, 190A, 181C, 108I
Pillay et al. CROI 2007. Abstr. 642.
• Undisclosed Prior ART !!!!.• Maybe it is important to
monitore cronic infected individuals in RLC.
www.ias2011.org
Summary
• Resistance develops following failure of therapy.• Resistance can be transmitted• Improvements in ARV regimens reduces
emergence and transmission of resistance• Extensive resistance may develop in absence of
cautious monitoring of ARV use.• Transmitted resistance is an important element in
the new approach of “test and treat” to tackle HIV transmission.
• Undisclosed prior ART in Resource Poor Settings can be an important element.
www.ias2011.org
Global distribution of HIV-1 subtypes and recombinants
in 2000–2003 and 2004–2007.• The global and regional
distributions of individual subtypes and recombinants are broadly stable.
• subtype C still accounts for nearly half (48%) of all global infections.
• CRF2_ AG doubled in 5 years.
Joris Hemelaar et al. AIDS 2011, 25:679–689
www.ias2011.org
HIV-2 in the world
• HIV-2 is prevalent in West Africa but can be also be found in other African Regions (Angola and Mozambique), and in Spain, Portugal, France, India, and Macau in micro-epidemics.
• The proportion of HIV-2 in AIDS Epidemic in Angola and Mozambique is 0.6% and 0.25% , respectively.
• HIV-2 is naturally resistant to NNRTI • HIV-2 accumulate more frequently
Q151M mutation when compared to HIV-1 individuals treated with AZT or d4T.
www.ias2011.org
Dinamics of HIV-2 infection in west Africa (Guine Bissau)- Project Bandim
• The amount of HIV-1/HIV-2 coinfection in west Africa is increasing and this can pose a threat to HAART therapies which target more the HIV-1.
• HIV-1/HIV-2 coinfection in west Africa can also be a important problem for the PMTCT interventions.
%
www.ias2011.org
Final Remarks
• The best way to prevent the spread of HIV DR is to prevent HIV infection.
• The best way to prevent the spread of HIV DR is to keep the patients in ARV with undetectable VL.
• In RLS the VL is not available in large scale.• 2nd line potent regimens are not available in
RLS.• We need to make na effort to implement VL and
make available potent 2nd line regimens to curb the spread of HIV DR.
www.ias2011.org
Grazie
Thank you
Obrigado
Top Related